Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Recruiting · Phase 2 · NCT06624475
Conditions: Basal Cell Carcinoma
At a glance
- Research payments reported, 2025
- $374,631
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- University of California, San Diego (with Bristol-Myers Squibb)
- Tested
- Nivolumab (drug), Relatlimab plus Nivolumab (drug)
- Dates
- Started 2025-08-21; completion 2028-05
- Results posted
- Not yet
This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)
From ClinicalTrials.gov, last updated 2026-07-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $374,631 in research payments for this study in 2025 (1 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of California San Diego $374,631
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.